Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지

Effects of Aerosol Colistin Treatment of Pneumonia Caused by Multi-drug Resistant Acinetobacter baumannii

다약제 내성 Acinetobacter baumannii 에 의한 폐렴에서 Colistin 분무치료의 효과

  • Choi, Hye Sook (Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Kyung Hee University College of Medicne) ;
  • Hwang, Yeon Hee (Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Kyung Hee University College of Medicne) ;
  • Park, Myung Jae (Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Kyung Hee University College of Medicne) ;
  • Kang, Hong Mo (Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Kyung Hee University College of Medicne)
  • 최혜숙 (경희대학교 의과대학 호흡기내과학교실) ;
  • 황연희 (경희대학교 의과대학 호흡기내과학교실) ;
  • 박명재 (경희대학교 의과대학 호흡기내과학교실) ;
  • 강홍모 (경희대학교 의과대학 호흡기내과학교실)
  • Received : 2007.11.29
  • Accepted : 2007.12.24
  • Published : 2008.01.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Acinetobacter infections are difficult to treat as they often exhibit multiple resistance to the antibiotics that are currently available for the treatment of pneumonia. Colistin is active against gram-negative bacteria, including the multiple drug resistant (MDR) Acinetobacter species. However, intravenous administration of colistin was abandoned because of its nephrotoxicity and neurotoxicity. The aims of this study were to examine the efficacy and safety of colistin administered by aerosol in the treatment of pneumonia caused by MDR Acinetobacter baumannii. Methods: We retrospectively reviewed the medical records of patients admitted to the intensive care unit (ICU) from Dec. 2006 to Aug. 2007 who had been diagnosed as suffering from pneumonia due to MDR Acinetobacter baumannii and had been treated with nebulized colistin. Results: 31 patients received aerosolized colistin. The average duration of the treatment was $14{\pm}7$ days and the daily dose of ranged from 225 mg to 300 mg. All patients received concomitant intravenous antimicrobial agents. The average length of the stay in the ICU was $34{\pm}21$ days and in the hospital $58{\pm}52$ days. The overall microbiological eradication was observed in 25 patients (80.6%). 14 of these (56%) were cured, and 11 (44%) were infected with other microorganisms. The overall crude mortality of the ICU was 48%. Nephrotoxicity and significant bronchial constriction did not occur in any patient during neublized colistin treatment. Conclusion: Nebulized colistin may be a safe and effective option in the treatment of pneumonia due to MDR Acinetobacter baumannii. Its role in therapy warrants further investigation in comparative studies.

연구배경: Acinetobacter baumannii는 항생제에 대한 내성균이 자주 발생하며 MDR Acinetobacter baumannii 감염의 치료 시 항생제 선택에 어려움이 있다. Colistin은 그람 음성균에 효과적이며 MDR Acinetobacter균에 감수성을 보이나 전신투여 시 신독성, 신경독성 등의 부작용으로 인해 잘 쓰이지 않는 약제이다. 전신투여에 의한 부작용을 회피하는 방법으로 분무치료가 있다. 그러나 MDR Acinetobacter baumannii 페렴환자에서 colistin 분무치료의 효과와 부작용에 대한 국내연구는 부족한 실정이어서 저자들은 다음과 같은 연구를 시행하였다. 방법: 2006년 12월부터 2007년 8월까지 중환자실의 폐렴환자 중에서 호흡기검체 배양검사를 통해 imipenem에 내성을 포함한 MDR Acinetobacter baumannii균에 의한 폐렴이 진단된 환자를 대상으로 하였다. 이들 중 항생제 정맥주사와 더불어 하루 3번의 colistin 분무치료를 시행했던 환자들의 의무기록을 후향적으로 분석하여 임상 소견, 신기능, 인공호흡기의 최대기도압의 변화를 분석 하였다 결과: 총 31명의 환자에서 colistin 분무치료를 시행하였다. Colistin 사용기간은 $14{\pm}7$일이었으며, 하루 흡입용량은 225~300 mg이었다. Colistin 분무치료 후 25명/31명(80.6%)에서 Acinetobacter균이 제거되었으나 이 중 11명(44%)에서는 2차 감염에 의한 새로운 균이 배양되었다. Colistin 분무치료 전, 후로 백혈구 수는 감소하였다. Colistin 분무치료 후 신기능의 장애는 발생하지 않았으며 의미 있는 기관지경련의 소견도 관찰되지 않았다. 결론: 적절한 항생제를 선택하기 어려운 MDR Acinetobacter baumanii에 의한 폐렴을 치료하는데 colistin 분무치료는 비교적 높은 균 제거율과 낮은 부작용을 보이므로 고려해 볼 수 있는 치료방법으로 사료된다.

Keywords

References

  1. Bergogne-Berezin E. The increasing significance of outbreaks of Acinetobacter spp.: the need for control and new agents. J Hosp Infect 1995;30 Suppl:441-52 https://doi.org/10.1016/0195-6701(95)90048-9
  2. Luna CM, Aruj PK. Nosocomial Acinetobacter pneumonia. Respirology 2007;12:787-91 https://doi.org/10.1111/j.1440-1843.2007.01147.x
  3. Cisneros-Herreros JM, Garnacho-Montero J, Pachon-Ibanez ME. Nosocomial pneumonia due to Acinetobacter baumannii. Enferm Infecc Microbiol Clin 2005; 23 Suppl 3:46-51 https://doi.org/10.1157/13091220
  4. Diomedi A. Acinetobacter baumannii pandrug-resistant: update in epidemiological and antimicrobial managing issues. Rev Chilena Infectol 2005;22:298-320
  5. Trottier V, Namias N, Pust DG, Nuwayhid Z, Manning R, Marttos AC, et al. Outcomes of Acinetobacter baumannii infection in critically ill surgical patients. Surg Infect (Larchmt) 2007;8:437-43 https://doi.org/10.1089/sur.2006.029
  6. Murray CK, Hospenthal DR. Treatment of multidrug resistant Acinetobacter. Curr Opin Infect Dis 2005;18:502-6 https://doi.org/10.1097/01.qco.0000185985.64759.41
  7. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005;40:1333-41 https://doi.org/10.1086/429323
  8. Beringer P. The clinical use of colistin in patients with cystic fibrosis. Curr Opin Pulm Med 2001;7:434-40 https://doi.org/10.1097/00063198-200111000-00013
  9. Kwa AL, Loh C, Low JG, Kurup A, Tam VH. Nebulized colistin in the treatment of pneumonia due to multidrugresistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2005;41:754-7 https://doi.org/10.1086/432583
  10. Michalopoulos A, Kasiakou SK, Mastora Z, Rellos K, Kapaskelis AM, Falagas ME. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrugresistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care 2005;9:R53-9 https://doi.org/10.1186/cc3020
  11. Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis 1988;138:720-3 https://doi.org/10.1164/ajrccm/138.3.720
  12. Wilks M, Wilson A, Warwick S, Price E, Kennedy D, Ely A, et al. Control of an outbreak of multidrug- resistant Acinetobacter baumannii-calcoaceticus colonization and infection in an intensive care unit (ICU) without closing the ICU or placing patients in isolation. Infect Control Hosp Epidemiol 2006;27:654-8 https://doi.org/10.1086/507011
  13. Ling ML, Ang A, Wee M, Wang GC. A nosocomial outbreak of multiresistant Acinetobacter baumannii originating from an intensive care unit. Infect Control Hosp Epidemiol 2001;22:48-9 https://doi.org/10.1086/501827
  14. Hanberger H, Garcia-Rodriguez JA, Gobernado M, Goossens H, Nilsson LE, Struelens MJ. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups. JAMA 1999;281:67-71 https://doi.org/10.1001/jama.281.1.67
  15. Paul M, Weinberger M, Siegman-Igra Y, Lazarovitch T, Ostfeld I, Boldur I, et al. Acinetobacter baumannii: emergence and spread in Israeli hospitals 1997-2002. J Hosp Infect 2005;60:256-60 https://doi.org/10.1016/j.jhin.2005.01.007
  16. Park II, Kim IK, Koo HC, Han JP, Kim YM, Lee MG, et al. Clinical characteristics and prognosis of acinetobacter nosocomial pneumonia between MDR and non-MDR. Tuberc Respir Dis 2006;61:13-9 https://doi.org/10.4046/trd.2006.61.1.13
  17. Lee SW, Jo HS, Kim WJ. Clinical characteristics of intensive care unit patients with carbapenem resistant acinetobacter baumannii isolated from sputum. Tuberc Respir Dis 2006;60:228-34 https://doi.org/10.4046/trd.2006.60.2.228
  18. Saballs M, Pujol M, Tubau F, Pena C, Montero A, Dominguez MA, et al. Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2006;58:697-700 https://doi.org/10.1093/jac/dkl274
  19. Pereira GH, Muller PR, Levin AS. Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant Gram-negative bacilli with inhaled polymyxin B. Diagn Microbiol Infect Dis 2007;58:235-40 https://doi.org/10.1016/j.diagmicrobio.2007.01.008
  20. Falagas ME, Kasiakou SK, Tsiodras S, Michalopoulos A. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin Med Res 2006;4: 138-46 https://doi.org/10.3121/cmr.4.2.138
  21. Wood GC, Swanson JM. Aerosolised antibacterials for the prevention and treatment of hospital-acquired pneumonia. Drugs 2007;67:903-14 https://doi.org/10.2165/00003495-200767060-00006
  22. Alothman GA, Ho B, Alsaadi MM, Ho SL, O'Drowsky L, Louca E, et al. Bronchial constriction and inhaled colistin in cystic fibrosis. Chest 2005;127:522-9 https://doi.org/10.1378/chest.127.2.522
  23. Reina R, Estenssoro E, Saenz G, Canales HS, Gonzalvo R, Vidal G, et al. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med 2005;31:1058-65 https://doi.org/10.1007/s00134-005-2691-4
  24. Lee MA, Moon HW. In vitro activity of antimicrobial combination against multidrug-resistant strains of acinetobacter baumannii. Korean J Lab Med 2005;25:312-6